ABL Diagnostics Announces Its Participation in Investor Access @ Maison De La Chimie Paris 2026

WOIPPY, France--(BUSINESS WIRE)--Regulatory News:

ABL Diagnostics (Euronext Paris – Compartment B – ISIN: FR001400AHX6 – ABLD), an international company specializing in molecular diagnostic solutions, healthcare software and life sciences services, announces its participation in Investor Access @ Maison de la Chimie Paris 2026, with Paris events on October 6–7, 2026.

Organized by Investor Access, these events connect listed companies with professional investors through targeted, pre-arranged meetings with management teams. The 2026 program brings together more than 190 professional investors and 90 listed companies across its events.

ABL Diagnostics’ Management will be available on October 6–7 for one-to-one meetings with investors to present the Company’s recent developments, growth strategy and outlook.

These discussions will provide an opportunity to review the evolution of ABL Diagnostics’ scope of activities, the international development of its operations and the strengthening of its positioning in the fields of molecular diagnostics, virology, viral safety and services for life sciences players.

PRACTICAL INFORMATION:

• Investor Access @ Maison de la Chimie Paris 2026
• October 6–7, 2026
• Maison de la Chimie – Paris

For more information about the event: https://www.investoraccess.fr/prog26/

MEET ABL DIAGNOSTICS:

Investors wishing to meet ABL Diagnostics’ Management during the October 6–7 event may contact:

• ABL Diagnostics S.A.
• [e-mail]
• [phone]
• https://www.abldiagnostics.com/contact/

or directly contact Investor Access:

Numa Pomirol

Investor Access

[e-mail]

[phone]

About ABL Diagnostics (ABLD)

ABL Diagnostics (ABLD) is an international company specializing in innovative molecular biology tests and comprehensive solutions for its customers:

• Molecular detection by polymerase chain reaction (PCR) – UltraGene, and
• Genotyping by DNA sequencing – DeepChek®.

ABL Diagnostics markets its entire product range worldwide through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics’ customers include academic clinical pathology laboratories, private reference laboratories and researchers seeking to implement innovative, robust and continuously expanding microbiology content.

Following the acquisition of TEXCELL’s activities, ABL Diagnostics is expanding its life sciences activities by integrating expertise and services dedicated to virology, biosafety testing and biopharmaceutical development.

ABL Diagnostics has marketed the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.

An expanding microbiology product portfolio:

• HIV – Drug resistance testing, including a whole genome kit.
• SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced detection solutions.
• Microbiome and taxonomy – Analyses based on 16S/18S RNA.
• Other viral and bacterial targets – Comprehensive molecular testing.

Integrated solutions

• Real-time syndromic PCR tests
• Nadis® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.

ABL Diagnostics, headquartered in Woippy, is a public limited company listed on Compartment B of the Euronext regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.

Société anonyme au capital de 1 611 465,60 euros
Headquarters : 72C route de Thionville - 57140 WOIPPY
552 064 933 R.C.S. METZ